BRENTWOOD, Tenn. / Dec 18, 2024 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing midsize urban communities across the U.S., today announced the Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference being held Jan. 13-16, 2025, in San Francisco.
The management team will present at the conference beginning at 2:15 p.m. PT on Tuesday, Jan. 14, 2025. A live audio webcast of the presentation will be available at the investor relations section of the Company’s website, at ir.ardenthealth.com, and a replay will be available for 90 days using the same link.
In conjunction with the conference, the Ardent management team will be available to participate in one-on-one meetings with investors registered to attend the conference. Interested investors should contact their J.P. Morgan representative to schedule meetings.
About Ardent Health
Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and more than 200 sites of care with over 1,800 affiliated providers across six states. For more information, please visit ardenthealth.com.
Last Trade: | US$12.42 |
Daily Change: | 0.64 5.43 |
Daily Volume: | 533,843 |
Market Cap: | US$1.770B |
March 31, 2025 February 26, 2025 November 06, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load